par Bartsch, Rupert;Berghoff, Anna Sophie;Zielinski, Christoph;Gnant, Michael;Frings, Stefan;Marty, Michel;Awada, Ahmad 
;Conte, PierFranco;Dickin, S.;Enzmann, Harald;Hasmann, Max;Hendriks, Hans H.R.;Llombart, Antonio;Massacesi, Cristian;Von Minckwitz, Gunter;Pénault-Llorca, Frederique;Scaltriti., Maurizio;Yarden, Yosef;Zwierzina, Heinz
Référence Annals of oncology, 25, 4, page (773-780), mdt531
Publication Publié, 2014
;Conte, PierFranco;Dickin, S.;Enzmann, Harald;Hasmann, Max;Hendriks, Hans H.R.;Llombart, Antonio;Massacesi, Cristian;Von Minckwitz, Gunter;Pénault-Llorca, Frederique;Scaltriti., Maurizio;Yarden, Yosef;Zwierzina, HeinzRéférence Annals of oncology, 25, 4, page (773-780), mdt531
Publication Publié, 2014
Article révisé par les pairs
| Résumé : | Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. |
